GlobeNewswire

New Predictive Analytics, Assurance Capabilities Advance Cisco's Strategy to Reinvent the Network for Digital Business

Del
  • Mathematical modeling and contextual insights represent the next major advancement in intent-based networking revolution
  • Waves of software innovation fuel evolution of networking portfolio toward subscription-led model
  • Cisco delivers an industry leading end-to-end intent-based networking portfolio, which spans the data center, campus, branch and edge

BARCELONA, Spain, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Cisco today announced powerful assurance innovations across its intent-based networking portfolio that will help IT teams shift from reactive to proactive. It will address the 43 percent of time IT spends troubleshooting, while making IT operations more proactive, agile and automated. The software innovations represent significant advancements in mathematical modeling and contextual insights, accelerating Cisco's strategy to reinvent the network for the digital era.

Over the past few years, the explosion of devices, adoption of cloud, and exponential growth of security threats have challenged current approaches for building and managing networks. Cisco's vision is to create a network that anticipates operational issues, stops security threats in their tracks, and continues to learn, adapt and protect. To realize this, Cisco is driving the intent-based networking revolution by transforming the entire network, from the data center and campus, to the branch and edge.

Today, Cisco is introducing its second wave of intent-based networking innovation, with powerful assurance products spanning the networking portfolio. 

  • In the data center, the Cisco Network Assurance Engine uses continuous verification of the entire network to help keep business running as intended, even as the network changes dynamically.
  • In campus and branch networks, Cisco DNA Center Assurance is delivering a new level of insight and visibility to dramatically reduce the time and money IT spends troubleshooting across wired and wireless environments.
  • And, for customers with distributed IT operations, the new Cisco Meraki Wireless Health reduces mean time to remediate wireless issues with rich analytics and insights.

"The network has never been more critical to business success," said David Goeckeler, executive vice president, Networking and Security Business at Cisco. "We're reinventing the network ground up to deliver a secure and intelligent platform for digital business. Today, we are taking another major step toward that ambitious goal with intent-based networking innovations designed to deliver contextual insights and assurance that will help transform IT from reactive to proactive."

Cisco's intent-based networking portfolio represents a fundamental shift away from the manual and time-intensive methods by which networks are traditionally managed. These intent-based networks capture and translate business intent into network policies, and activate them across the infrastructure. With the introduction of assurance capabilities, they can now continuously verify the network is operating as intended.

Customers globally are embracing intent-based networking. Nearly 200 customers are in early field trails with the new assurance technologies, including Robert Bosch GmbH, REWE Group, Houston Methodist Hospital and Scotiabank. More than 1,100 customers are deploying the recently announced Catalyst 9000 Series switches, with 150 running DNA Center pilots. In the data center, Cisco has more than 14,500 Nexus 9000 customers, with a 45 percent ACI attach rate.

Innovation Spanning Data Center and Enterprise Networking 
Today, Cisco is introducing three powerful new assurance products that further demonstrate how intent-based networking systems move at the speed of digital business.

In the data center network, Cisco is enabling always-on assurance through the Cisco Network Assurance Engine. By combining mathematically accurate models of the network with more than 30 years of codified domain knowledge, Cisco provides IT teams the ability to instantly pinpoint why and when the network is not acting as intended, then offer suggestions on how to address the issue. This comprehensive view into their network helps enable IT teams to:

  • Predict the Impact of Changes: Make changes to the network faster and with more confidence, catching human configuration errors before they cause problems.
  • Continuously Verify Network Behavior: Proactively eliminate network outages and vulnerabilities by continuously analyzing the state of the entire network.
  • Assure Security Policy and Compliance: Reduce risk by assuring that security policies are being applied consistently across the network, and ensure policies are compliant with business requirements-every minute of every day.

With ACI and Tetration, Cisco provides the ability to translate application intent and activate those policies across the network. Now, with the Network Assurance Engine, Cisco is delivering the final element of intent-based networking - the assurance of intent.

In the campus and branch, Cisco is enabling 'everything as a sensor' and aggregating intelligence from the network, application, client and things to help provide IT with full context. These capabilities will dramatically reduce the 43 percent of time that IT spends troubleshooting and improve the experience for employees and customers.

Cisco DNA Center Assurance provides a 360-degree contextual view that connects all the relationships of who, what, where, when, how. Spanning wired and wireless environments, it delivers a complete picture of what is happening between users and applications with real-time, historical and predictive capabilities. DNA Center Assurance helps IT teams address three major issues:

  • Problem Isolation: Get to the root cause in minutes-not days or weeks-by isolating where exactly the issue happened.
  • Problem Replication: Go back in time to when an issue occurred. IT can view a complete 360 snapshot of the status of the network, user, device and application at the exact moment the issue arose.
  • Problem Resolution: Proactively fix the issue through guided remediation.

With Cisco Meraki Wireless Health, IT also gains visibility and rich analytics to troubleshoot wireless issues faster and deliver a better user experience. Cisco Meraki uses a cloud-managed IT model to automate operations, simplifying the complexity of IT. Now, Meraki Wireless Health allows IT teams to quickly identify wireless anomalies, find poorly performing access point and clients, and provide actionable insights to improve the wireless experience.

Powered by network analytics and rich contextual data, Cisco Services offers new services to help customers streamline the deployment of the new assurance solutions. From advisory and implementation, through optimization and managed services, Cisco and its partners are helping customers accelerate their journey to truly intent-based networks.

Customer Quotes
Robert Bosch GmbHJan Holzmann, Team Lead for Data Center Network Operations
"We are constantly bringing on new applications and expanding our data center capacity as we expand our business. The Cisco Network Assurance Engine helps enable a new level of quality for our application migrations. With a detailed understanding of the policy model and proactive verification of all changes, Cisco Network Assurance Engine can help us greatly reduce the risk of production outages and accelerate our timelines."

Houston Methodist Hospital, Manuel Ortiz III, Senior Wireless Engineer
"DNA Center helps me find problems proactively, before users contact me. With a mostly wireless network, I'm able to find devices throughout the network and quickly solve any problems with the help of analytics."

Axians Nordic, Erik Sohlman, Senior Manager and CTO
"As a Cloud Service Provider, our business depends on network availability and delivering on customer SLAs. We are always looking for modern technologies to manage our multiple data centers and remain an industry leader.  Cisco Network Assurance Engine's approach of 'always on assurance' for our network and services will make our operating model more proactive and help enable us to remain as the best-in-class service provider to our customers."

REWE Group, Hans Vasters, Senior Network Architect
"Cisco DNA Center allows the networking team to focus on our core projects and give more responsibility to the first line support team. It lets our team be proactive when it comes to resolving issues, before it becomes a problem to our users."

Scotiabank, Nicholas Yurkovich Chief Network Engineer
"The more intuitive that I can make troubleshooting, the sooner I can take the network out of the equation. With Cisco DNA Center Assurance, the Scotiabank first line support teams can now take a proactive approach to resolving wireless issues and the engineering networking teams can work on growth and forward-looking opportunities."

West Corporation, Tania Mazza, Director, Network Engineering
"At West, we run critical communications infrastructure for our customers, and as such, scale and speed are vital for our operations. Using the change verification process, we see Cisco Network Assurance Engine as a way to achieve higher levels of automation with increased certainty, allowing us to confidently move at a faster pace."

Availability

  • The Cisco Network Assurance Engine is available now, initially for Cisco ACI customers, with a free, 30-day, no-commitment trial. Customers can purchase it via software subscription.
  • Cisco DNA Center Assurance is available now. Customers can purchase it via the Cisco ONE subscription offer for networking.
  • Cisco Meraki Wireless Health is expected to be available in early 2018. It will be included with the standard subscription for Meraki Wireless Access Points.

Additional Resources

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the United States and certain other countries. A listing of Cisco's trademarks can be found at  www.cisco.com/go/trademarks .  All other trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. Many of the products and features described herein remain in varying stages of development and will be offered on a when-and-if-available basis. This roadmap is subject to change at the sole discretion of Cisco, and Cisco will have no liability for delay in the delivery or failure to deliver any of the products or features set forth in this document. This document is Cisco Public Information.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Gareth Pettigrew
Cisco
+1 (604) 647-2326 
gpettigr@cisco.com

Lee Davis                                                                                              
Cisco                                                                                                           
650-868-3036                                                                                                                    
leedavis@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t

CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00Pressemelding

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos

Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00Pressemelding

Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00Pressemelding

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated

GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12Pressemelding

SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00Pressemelding

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist